Chris Martin mortified after catching Astronomer CEO, HR chief on Coldplay kiss cam: ‘Hope we didn't do something bad'
A mortified Chris Martin struggled to carry on his concert Wednesday night after cameras at his Boston show caught Astronomer CEO Andy Byron allegedly cheating on his wife with his HR chief Kristin Cabot.
'I hope we didn't do something bad…' Martin said in a newly surfaced clip from the show that was shared on X.
The businessman and Cabot made headlines on Thursday morning after a video of them being caught on the concert's kiss cam went viral.
In the clip that's been circulating on social media, the pair were seen swaying with their hands wrapped around each other as Martin moved the 'kiss cam' around Gillette Stadium.
'Look at these two,' the 'Yellow' hitmaker, 48, said.
The pair appeared to be horrified by the camera catching them off guard as Cabot immediately turned around and Byron ducked out of view.
'Either they're having an affair or they're just very shy,' Martin added, which elicited a string of equal cheers and gasps from the audience.
Soon after the incident set the internet ablaze, Byron's wife, Megan Kerrigan Byron, deleted her social media page.
And shortly before taking down her profile, she deleted her surname from her account.
As we previously reported, Byron became the CEO for the New York-based business in July 2023, according to his since-deleted LinkedIn account.
Cabot later joined the company as its chief human resources officer in November 2024. However, a post announcing her role has since been wiped from her LinkedIn page.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio
Fox News
8 minutes ago
- Fox News
'Ruthless' applauds Trump's late-night fight: 'Take it back to basics'
'Ruthless' podcast co-hosts Michael Duncan, Comfortably Smug and John Ashbrook join 'Fox & Friends' to break down the fallout from CBS parting ways with 'The Late Show' and host Stephen Colbert.
Fox News
8 minutes ago
- Fox News
'The View' host Sunny Hostin warns Colbert cancellation could lead to the 'dismantling of our Constitution'
"The View" co-host Sunny Hostin warned on Tuesday that CBS canceling Stephen Colbert's "Late Show" could be the start of the "dismantling of our Constitution." CBS announced Thursday "The Late Show" will end in May at the end of its broadcast season. Though CBS and parent company Paramount said the choice to cancel the series was "purely a financial decision," and the show was reportedly losing the network $40 million a year, many liberal commentators claim it was for political reasons. Just days before the cancellation, Colbert slammed Paramount's recent settlement with President Donald Trump over his lawsuit against "60 Minutes" as a "big fat bribe" ahead of a pending merger between Paramount and Skydance Media. Hostin and her fellow co-hosts were also skeptical of CBS' explanation for canceling Colbert's show based on the "timing" of the announcement. She pointed out that if politics were involved, then the fabric of democracy could be in jeopardy. "My concern is, if it is political, then everyone should be concerned. People on the right should be concerned. People on the left should be concerned. Because it's very clear that, if it is political, this is the dismantling of our democracy. This is the dismantling of our Constitution. Right?" Hostin said to the cheering of the studio audience. She continued, "The First Amendment is the First Amendment for a reason and that is freedom of the press, freedom of speech. Freedom to speak truth to power. If that is taken away, if the comedians are being attacked, then that means our Constitution is being dismantled… That means the very rubric of our democracy is being dismantled. And I think every single person should be really, really concerned about it." Hostin praised Sens. Elizabeth Warren, D-Mass., and Bernie Sanders, I-Vt., for speaking up on the issue and demanding answers. Several other high-profile Democrats also spoke out against canceling Colbert, whose show was openly favorable to their party while hostile to Republicans. "We must protect our Constitution and we must protect our democracy! This is bigger than just the cancellation of a television show!" Hostin exclaimed. Her co-host Joy Behar blamed Trump for Colbert's cancellation and warned "all bets are off" if comedians are taken down. "It's always been the role of the court jester to make fun of the king. That is the role of comedians. I have said on this show, I think I said it years ago, when they start coming for the comedian, all bets are off, because the king is supposed to take the hits and this guy has a skin thinner than, I don't know, than this card," Behar said, holding one up. Colbert fired back against Trump on his show Monday night after the president celebrated his show ending on Truth Social, writing, "I absolutely love that Colbert got fired. His talent was even less than his ratings. "How dare you, sir?" Colbert responded. "Would an untalented man be able to compose the following satirical witticism? Go f--- yourself."
